Table 1

Characteristics of the included studies

Study (registration number)Disease settingStudy phaseExperimental armControl armTotal N≥65 years (%)Elderly (N)Young (N)
ExpCtrlExpCtrl
ARIEL3 (NCT01968213)Platinum-sensitiveIIIRucaparib 1200 mg/dailyPlacebo/daily56437.213872237117
VELIA/GOG-3005 (NCT02470585)Primary advancedIIICarboplatin AUC 6+paclitaxel 175 mg/mq q3w+veliparib 300 mg/daily or carboplatin AUC 6+paclitaxel 175 mg/mq+veliparib 300 mg → Veliparib 600–800 mg/daily maintenanceCarboplatin AUC 6+paclitaxel 175 mg/mq q3w+placebo/daily → Placebo/daily maintenance75739.1154142228233
PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016)Primary advancedIIINiraparib 200 or 300 mg/dailyPlacebo/daily73339.419099297147
SOLO1 (NCT01844986)Primary advancedIIIOlaparib 600 mg/dailyPlacebo/daily39113.83519225112
PAOLA-1 (NCT02477644)Primary advancedIIIOlaparib 600 mg/daily+bevacizumab 15 mg/kg q3wPlacebo/daily+bevacizumab 15 mg/kg q3w80636.220587332182
ENGOT-OV16/NOVA (NCT01847274)Platinum-sensitiveIIINiraparib 300 mg/dailyPlacebo/daily55335.313263240118
SOLO2/ENGOT-OV21 (NCT01874353)Platinum-sensitiveIIIOlaparib 300 mg/twice dayPlacebo/twice day29521.0402215677
NORA (NCT03705156)Platinum-sensitiveIIINiraparib 300 mg/dailyPlacebo/daily26514.0251215276
  • AUC, area under the curve.